Study of Nanrilkefusp Alfa Alone and With Pembrolizumab in Adult Patients With Advanced/Metastatic Solid Tumors
Summary
The registered summary isn't in our current data snapshot. Read it on the ClinicalTrials.gov record ↗. Why? →
Investigators
The overall officials registered on this study. Names that resolve to a findmyKOL profile link to it; the rest are shown as registered.
- Stephane Champiat, Dr.
Institute Gustave Roussy, Villejuif, France
Principal Investigator
A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.
Sites
12 registered facilities, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.
- Masarykův Onkologický Ústav Brno Klinika Komplexní Onkologické Péče
Brno, Czechia, Czechia
- Centre Léon Bérard
Lyon, France, France
- Institut Gustave Roussy
Paris, France, France
- Institut Claudius Regaud
Toulouse, France, France
- Hôpitaux Universitaires de Marseille Timone
Marseille, France
- Hopital Saint Louis
Paris, France
- Institut de Cancerologie de L'Ouest
Saint-Herblain, France
- Vall D'Hebron Institute of Oncology
Barcelona, Spain, Spain
- University Hospital Sanchinarro
Madrid, Spain
- Yale Cancer Center
New Haven, Connecticut, United States
- University of Pittsburgh
Pittsburgh, Pennsylvania, United States
- Md Anderson Cancer Center
Houston, Texas, United States
Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.
Drugs studied
No drug or biological interventions are in our data for this study — it may test a procedure, device or behavioral intervention, or the intervention list isn't in our current snapshot. See the registry record ↗. Why? →
Registration & key dates
Registry attributes as recorded on the ClinicalTrials.gov study record.
- Start
- 13 Jun 2019
- Primary completion
- 31 Aug 2024
- Completion
- 27 Nov 2024
- Last update posted
- 27 Mar 2026
- Registered enrollment
- 115
- Registry id
- NCT04234113
Cross-registrations
Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 12 Jul 2026. Registry facts are shown as registered by the study sponsor; findmyKOL does not interpret them.